Renuka Dahiya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Renuka Dahiya has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Freywald
University of Saskatchewan
74 shared publications - Franco J. Vizeacoumar
Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Canada
74 shared publications - Aaron P. White
University of Saskatchewan
73 shared publications - Amr El Zawily
Department of Plant and Microbiology, Faculty of Science, Damanhour University, Damanhour 22511, Egypt
73 shared publications - Behzad M. Toosi
Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, 52 Campus Drive, Saskatoon, SK S7N 5B4, Canada
73 shared publications - Bingcheng Wang
Division of Cancer Biology, Department of Medicine, MetroHealth Center for Cancer Research, MetroHealth Campus, Case Western Reserve University, Cleveland, OH, United States
73 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Springer Nature in Nature Communications
A lactate-fatty acid loop drives prostate cancer bone colonization by mediating metabolic interplay between tumor cells and osteoblasts
Bone metastasis is the major cause of morbidity and mortality in advanced prostate cancer, yet current therapies provide only limited clinical benefit. Here, we show that prostate cancer cells metabolically adapt to the bone microenvironment by utilizing bone-cell-derived lactate as an alternative nutrient source. Beyond fueling oxidative phosphorylation, lactate serves as carbon source for fatty acid synthesis. Among the resulting lipid products, oleic acid is secreted to reward osteoblast, establishing a reciprocal metabolic interplay that supports both tumor progression and pathological bone formation. Mechanistically, we identify MCT1 as the essential transporter mediating lactate uptake in bone-colonizing tumor cells. MCT1 expression is coordinately regulated by NFAT signaling and extracellular glucose availability at both transcriptional and post-translational levels. Genetic deletion and pharmacological inhibition of MCT1 markedly suppresses prostate tumor growth in bone. Together, these findings uncover a lactate-driven metabolic crosstalk, identifying MCT1 as a promising therapeutic target for prostate cancer bone metastasis.
- 10 November 2026
- Published by Springer Nature in Nature Communications
Open AccessA lactate-fatty acid loop drives prostate cancer bone colonization by mediating metabolic interplay between tumor cells and osteoblasts
Bone metastasis is the major cause of morbidity and mortality in advanced prostate cancer, yet current therapies provide only limited clinical benefit. Here, we show that prostate cancer cells metabolically adapt to the bone microenvironment by utilizing bone-cell-derived lactate as an alternative nutrient source. Beyond fueling oxidative phosphorylation, lactate serves as carbon source for fatty acid synthesis. Among the resulting lipid products, oleic acid is secreted to reward osteoblast, establishing a reciprocal metabolic interplay that supports both tumor progression and pathological bone formation. Mechanistically, we identify MCT1 as the essential transporter mediating lactate uptake in bone-colonizing tumor cells. MCT1 expression is coordinately regulated by NFAT signaling and extracellular glucose availability at both transcriptional and post-translational levels. Genetic deletion and pharmacological inhibition of MCT1 markedly suppresses prostate tumor growth in bone. Together, these findings uncover a lactate-driven metabolic crosstalk, identifying MCT1 as a promising therapeutic target for prostate cancer bone metastasis.
- Open Access
- 4 June 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 213
Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancers
Tumor heterogeneity presents a major clinical challenge. Reactivation of telomerase (hTERT) is a near-universal hallmark of cancer, yet direct inhibition of hTERT has shown limited therapeutic benefit. To uncover tractable telomerase-related vulnerabilities, we applied a synthetic dosage lethality (SDL) strategy to identify genes required only when hTERT is overexpressed. We performed genome-wide CRISPR/Cas9 and shRNA screens across multiple isogenic cell line pairs differing in hTERT expression. From these datasets, 100 high-confidence candidates were prioritized and validated using an arrayed in vitro CRISPR screen and a pooled in vivo CRISPR screen across diverse cancer models, non-malignant cells, and patient-derived organoids. Through this pipeline, we identified FTSJ3, an RNA 2′-O-methyltransferase, as a top SDL target of hTERT. Depletion of FTSJ3 selectively impaired the viability of hTERT-positive cancer cells while sparing normal cells. Mechanistically, FTSJ3 installs 2′-O-methylation on the telomeric RNA TERRA, a modification essential for TERRA stability and function. Loss of FTSJ3 destabilizes TERRA, disrupts recruitment of the histone methyltransferase SUV39H1, and diminishes H3K9 trimethylation and HP1 assembly at sub-telomeric regions. This breakdown of repressive telomeric chromatin leads to genome instability and apoptosis specifically in hTERT-positive cells. These findings highlight SDL as a powerful strategy for uncovering targetable vulnerabilities and establish FTSJ3 as a central regulator of heterochromatin stability in telomerase-active cancers. Targeting FTSJ3 enzymatic activity offers a promising therapeutic entry point, acting upstream of TERRA to eliminate telomerase-driven malignancies selectively.
- 4 June 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 213
Open AccessEpigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancers
Tumor heterogeneity presents a major clinical challenge. Reactivation of telomerase (hTERT) is a near-universal hallmark of cancer, yet direct inhibition of hTERT has shown limited therapeutic benefit. To uncover tractable telomerase-related vulnerabilities, we applied a synthetic dosage lethality (SDL) strategy to identify genes required only when hTERT is overexpressed. We performed genome-wide CRISPR/Cas9 and shRNA screens across multiple isogenic cell line pairs differing in hTERT expression. From these datasets, 100 high-confidence candidates were prioritized and validated using an arrayed in vitro CRISPR screen and a pooled in vivo CRISPR screen across diverse cancer models, non-malignant cells, and patient-derived organoids. Through this pipeline, we identified FTSJ3, an RNA 2′-O-methyltransferase, as a top SDL target of hTERT. Depletion of FTSJ3 selectively impaired the viability of hTERT-positive cancer cells while sparing normal cells. Mechanistically, FTSJ3 installs 2′-O-methylation on the telomeric RNA TERRA, a modification essential for TERRA stability and function. Loss of FTSJ3 destabilizes TERRA, disrupts recruitment of the histone methyltransferase SUV39H1, and diminishes H3K9 trimethylation and HP1 assembly at sub-telomeric regions. This breakdown of repressive telomeric chromatin leads to genome instability and apoptosis specifically in hTERT-positive cells. These findings highlight SDL as a powerful strategy for uncovering targetable vulnerabilities and establish FTSJ3 as a central regulator of heterochromatin stability in telomerase-active cancers. Targeting FTSJ3 enzymatic activity offers a promising therapeutic entry point, acting upstream of TERRA to eliminate telomerase-driven malignancies selectively.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S6: Hits from the EPHA2 BioID assay.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S6: Hits from the EPHA2 BioID assay.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S4: Hits from the genome-wide shRNA screen in αEPHA2-Cond cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S4: Hits from the genome-wide shRNA screen in αEPHA2-Cond cells.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Fig. S3. A. Correlation cluster for both the replicates and different timepoints of the screeningdata. B. Fold-change distribution from the normalized shRNA intensity for the αEPHA2-Condand cIgG-Tr cells at different time points. C. Precision-recall curves after applying BAGELalgorithm to the screening data. F measure provided in the inset represents the harmonic mean ofprecision & recall of the screen.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Fig. S3. A. Correlation cluster for both the replicates and different timepoints of the screeningdata. B. Fold-change distribution from the normalized shRNA intensity for the αEPHA2-Condand cIgG-Tr cells at different time points. C. Precision-recall curves after applying BAGELalgorithm to the screening data. F measure provided in the inset represents the harmonic mean ofprecision & recall of the screen.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S7: GO analysis of the BioID assay.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S7: GO analysis of the BioID assay.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S3: GO analysis of phosphorylated proteins differentially expressed in αEPHA2-Cond and cIgG-Tr cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S3: GO analysis of phosphorylated proteins differentially expressed in αEPHA2-Cond and cIgG-Tr cells.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Fig. S2. A. Heatmap of the differentially expressed phosphorylated proteins that are enriched inthe top 15 gene ontology (GO) processes generated using GSEA software. B. Gene SetEnrichment Analysis plots of the top 15 GO processes for the differentially expressedphosphorylated proteins data produced by GSEA software used to generate the heatmap in A.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Fig. S2. A. Heatmap of the differentially expressed phosphorylated proteins that are enriched inthe top 15 gene ontology (GO) processes generated using GSEA software. B. Gene SetEnrichment Analysis plots of the top 15 GO processes for the differentially expressedphosphorylated proteins data produced by GSEA software used to generate the heatmap in A.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S2: Protein phosphorylation events distinct in αEPHA2-Cond and cIgG-Tr cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S2: Protein phosphorylation events distinct in αEPHA2-Cond and cIgG-Tr cells.